BEIJING – Five-year-old Jacobio Pharmaceuticals Co. Ltd., of Beijing, has found itself a strong global partner to help advance its two SHP2 inhibitors, JAB-3068 and JAB-3312, both financially and later in the regulatory process. The Chinese startup will work with pharma giant Abbvie Inc., of North Chicago, to develop and commercialize the programs. Read More

SUZHOU, China – After growing rapidly in recent years, China’s pharma market will begin to see that growth slow, but market watchers said it is not necessarily all bad news. Read More

SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed. Read More

SUZHOU, China – Chinese CAR T therapy developers from early to IPO-ready-stage are confident that they can create a strong presence in the global scene with their innovations, and they are also making strategies that will work best for their home market. Read More

Swept up into a coronavirus whirlwind, the biopharma industry has ramped up development of therapeutics and vaccines and altered business plans to fight the SARS-CoV-2 virus in a way that nobody could have imagined only months ago. Read More

SUZHOU, China – With the outbreak tightly contained, business activities are starting to get back to normal in China. Opening in Suzhou on Thursday, the Enmore Bio Conference 2020 is one of the first industry galas to take place since the coronavirus hit the country. In the opening session, Chinese biotech insiders pointed to a bumpy road ahead for Chinese companies in the post-COVID-19 era.   Read More

LONDON – The World Health Organization (WHO) is stepping up its effort to try and ensure equitable access to any approved COVID-19 vaccines and therapies, putting in place a system for sharing all intellectual property, information and clinical trials data needed to enable generic manufacturing. Read More

With some positive early data for an antibody to block the COVID-19 virus, Sorrento Therapeutics Inc. is now looking to test a product in a few dozen intensive care patients by the end of July or early August and move into a much broader pool of patients by October. Read More

Prescient Therapeutics Pty Ltd. is poised to develop next-generation CAR T therapies after signing a deal with the University of Pennsylvania for a universal immune receptor technology platform. Read More

HONG KONG – South Korea’s Qurient Co. Ltd., located in Gyeonggi-do, is preparing to send its novel drug, Q-702, into the clinic after receiving clearance from the U.S. FDA. Read More

The juggernaut that is Daiichi Sankyo Co. Ltd.’s Enhertu continued to roll into this weekend’s American Society of Clinical Oncology virtual meeting, bringing momentum from its December FDA approval for HER2-positive breast cancer, along with fresh data from three new studies in other indications. Read More

Fidget spinners are hand-held toys based on a roller bearing and three weighted lobes, which can spin freely, creating centrifugal force when activated manually. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abbvie, Aerpio, Alligator, Anixa, Astrazeneca, Beigene, Biogen, Biotheus, Bold, Carna, Ceapro, Chimeron, Codiak, Daiichi Sankyo, Edigene, Eli Lilly, Emergent, Fujifilm, Heat Biologics, Hitgen, Hua Medicine, Humanigen, Immunitybio, Immunochina, Immutep, Innovation, Jacobio, Kalytera, Mateon, Merck, Moderna, Nantkwest, Novavax, Oncodesign, Ontochem, Organicell, Orpro, Oryzon Genomics, Oxford Biomedica, Praha Vaccines, Proteona, Proteostasis, Puretech, Rakuten Medical, Restorbio, Resverlogix, Seranovo, Shanghai Junshi, Shionogi, Synairgen, Takeda, Tetra, Tolero, Tonix, Toshiba, Twist, Vault, Vir, Virna. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Genetic Technologies, Outlook, Pneumagen. Read More

The latest global regulatory news, changes and updates affecting biopharma, including: Blue Dog Coalition, FDA, U.S. House and Senate. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Apellis, Atriva, Belx Bio-Pharmaceutical (Taiwan), Calcimedica, CTI Biopharma, Genentech, Gilead Sciences, Glenmark, I-Mab, Mesoblast, Moderna, Novavax, NS Pharma, Partner, Radius Health, Synairgen, Taiwan Liposome, Teijin, Transcenta, Zai Lab. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Abivax, Accord Healthcare, Akeso, Algernon, Altimmune, Anivive Lifesciences, Astellas, Beyond Air, Cerecor, Diffusion, Hutchison China Meditech, Immunitybio, Longeveron, Moleculin, Opko Health, Orpheris, Phasebio, Qurient, Radius Health, Shanghai Henlius, Shionogi, Sino, Takeda, Teijin. Read More

Data presented at the American Society of Clinical Oncology’s annual meeting. Read More